Ulcerative colitis improved by a multiple donor microbiota transplant
Ulcerative colitis (UC) is one of the chronic inflammatory diseases of the bowl and rectum (CIBD) where soft, bloody stools alternate with normal transit. The intestinal microbiota is suspected of being involved in the development of this disease. Fecal transplant constitutes one of the possible treatments. This procedure is generally done from stool of a single donor with a healthy microbiota. In this clinical trial published in The Lancet, the authors assess the possible benefit of fecal transplant combining several donors in patients with moderate UC. The results show that an 8-week intensive administration (5 times a week) of mixtures of intestinal microbiota from several donors leads to an improvement of disease symptoms in 27% of patients treated. These beneficial effects, verified by follow-up examinations (colonoscopy), persisted at least 8 weeks after the end of treatment. The study conclusions are rather optimistic, suggesting that the clinical remissions observed are related to the change in the intestinal flora of the recipient patients. New studies on the efficacy of these fecal transplants, or microbiota transplant, are necessary to adjust the treatment dosage to the severity of symptoms and the nature of patients’ initial microbiota.
S Paramsothy et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.Lancet 2017 Mar 25;389(10075):1218-1228. https://www.ncbi.nlm.nih.gov/pubmed/28214091